Pharmacokinetics and safety evaluation of intravenously administered Pseudomonas phage PA_LZ7 in a mouse model
Related Experiment Video
Updated: Jun 21, 2026
Pseudomonas aeruginosa Induced Lung Injury Model
Published on: October 29, 2014
Si-Yun Wang1, Xin Tan2, Zi-Qiang Liu2
1Department of Neonatology, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Child Infection and Immunity, Chongqing Key Laboratory of Pediatrics , Chongqing, China.
Importance:
Phage therapy is gaining traction as an alternative to antibiotics due to the rise of multi-drug-resistant (MDR) bacteria. This study assessed the pharmacokinetics and safety of PA_LZ7, a phage targeting MDR Pseudomonas aeruginosa, in mice. After intravenous administration, the phage showed an exponential decay in plasma and its concentration dropped significantly within 24 h for all dosage groups. Although there was a temporary increase in certain plasma cytokines and spleen weight at higher dosages, no significant toxicity was observed. Therefore, PA_LZ7 shows potential as an effective and safe candidate for future phage therapy against MDR P. aeruginosa infections.
Insights
PA_LZ7 phage therapy shows promise against multi-drug-resistant Pseudomonas aeruginosa. Studies in mice indicate it is safe and effective, with rapid clearance from the body and no significant toxicity observed.
Area of Science:
- Microbiology
- Pharmacology
- Infectious Diseases
Background:
- Antibiotic resistance is a growing global health threat.
- Phage therapy offers a potential alternative to antibiotics for treating bacterial infections.
- Multi-drug-resistant (MDR) Pseudomonas aeruginosa is a significant pathogen in healthcare settings.
Purpose of the Study:
- To evaluate the pharmacokinetics and safety of PA_LZ7, a bacteriophage targeting MDR P. aeruginosa.
- To determine the in vivo behavior and potential toxicity of PA_LZ7 in a mouse model.
Main Methods:
- Intravenous administration of PA_LZ7 phage to mice.
- Monitoring of phage plasma concentration over time.
- Assessment of plasma cytokines and spleen weight as indicators of toxicity.
Main Results:
- PA_LZ7 exhibited exponential decay in plasma, with concentrations significantly reduced within 24 hours across all tested doses.
- Higher doses of PA_LZ7 led to temporary increases in specific plasma cytokines and spleen weight.
- No significant overall toxicity was observed in the mouse model.
Conclusions:
- PA_LZ7 demonstrates favorable pharmacokinetic properties and a good safety profile in mice.
- PA_LZ7 is a potential candidate for further development as a therapeutic agent against MDR P. aeruginosa infections.
- Phage therapy with PA_LZ7 warrants further investigation for clinical applications.
More Related Videos
09:17A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
Published on: January 2, 2017
08:34Generation of In-Frame Gene Deletion Mutants in Pseudomonas aeruginosa and Testing for Virulence Attenuation in a Simple Mouse Model of Infection
Published on: January 8, 2020
